Compare Ferrari NV (RACE) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Tempus AI — how do they compare? Ferrari NV trades at $387.62 (market cap $68.13B), while Tempus AI trades at $69.99 (market cap $12.77B). The key difference: Ferrari NV is far larger — about 5.3× Tempus AI's market cap, and Ferrari NV pays a 1.09% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Tempus AI for 22 Days on average.
| RACE | TEM | |
|---|---|---|
Market Cap | $68.13B | $12.77B |
Volume | 480,007 | 8,980,490 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $436.54 | $99.28 |
52-Week Low | $314.63 | $41.55 |
Typical Hold Time | 126 Days | 22 Days |
Enterprise Value | $70.01B | $13.40B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $386.39, down 0.03% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily from 2022 to 2025, supported by robust profitability margins. Recent news highlights a share buyback program and strategic partnerships, while institutional investors show increased interest.
The outlook remains positive due to strong financial performance and analyst consensus, with a price target of $462.75 implying ~20% upside. Risks include high valuation multiples, economic sensitivity, and execution challenges in electric vehicle initiatives. The stock offers growth potential but requires monitoring of competitive and macroeconomic pressures.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
